FDA Poised to Make Impact on Underrepresented Populations in Clinical Studies
H1 Blog
JULY 30, 2024
The recent draft by the FDA introduces additional guidelines for Diversity Action Plans aimed at improving diversity in clinical research. We’re curious to see what will happen over the next 12 months and how pharma companies will respond.” Find out more by requesting a demo today.
Let's personalize your content